CardiacSense is a privately-owned startup that develops state of the art Bio-Sensing technology since 2012.
CardiacSense has developed the world first clinically proven medical wearable device for monitoring heart arrhythmias.
The company is focused on Atrial Fibrillation, Blood Pressure and Cardiac Arrest.
The company has won a contract from a tier-1 wristwatch manufacturer to develop an algorithm for continuous wrist-based Blood Pressure .
CardiacSense technology is based on a strong IP portfolio spread over the fields of optics, mechanics and signal processing.
In November 2017, CardiacSense signed an external investment agreement to raise $750,000 from a private foreign investor, at a valuation of $12 million. The financing represented a 20% rise in value compared with the $600,000 raised the previous month from existing shareholders at a company valuation of $10 million before money, of which Merchavia’s share was 12%.
Atrial Fibrillation (A-Fib) is the most common heart arrhythmia disorder and a major cause of strokes (x5) and mortality (x2). It is estimated that 1 out of 3 patients is un-diagnosed. The only continues solution in the market for detecting A-Fib is invasive. A-Fib US annual cost is 26B$, 35B$ in China and 30B$ in Europe.
Sudden Cardiac Arrest is the largest cause of natural death in the U.S., causing about 325,000 adult deaths in the U.S. each year. Mortality rate from CA is 90%. There is no solution in the market today for continues (24/7) detection of Cardiac Arrest that doesn’t interfere with day to day life. The total aggregate cost of Out of Hospital CA in the United States was $33 billion each year (Kida et al., 2014).
Global blood pressure monitoring devices market was valued at 2.08B$ in 2014 and is expected to grow at CAGR of over 11.0% over the forecast period. No solution for continues, cuff-less, non-invasive blood pressure monitor.